Ang II administration also enabled substantial norepinephrine dose reductions and was associated with favorable renal outcomes, including reduced initiation of renal replacement therapy (RRT), without an observed increase in major adverse events such as thromboembolism or digital ischemia [10]. This evidence concerns the gene AGT and Thromboembolism.